LIST OF FIGURES

Sr. No.	Title	Page No.
Chapter 1	**Introduction**	
Figure 1	Interplay of genes, environment (ROS generation) and immune system in precipitation of Vitiligo	2
Figure 2	Clinical types of vitiligo	5
Figure 3	A diagrammatical cross-section of human skin	6
Figure 4	Migration of melanocytes from the neural crest	7
Figure 5	Epidermal Melanin unit	8
Figure 6	Structure of melanosome	9
Figure 7	The melanin biosynthetic pathway	11
Figure 8	The events that support the neurochemical pathogenesis of vitiligo	15
Figure 9	Intracellular generation of ROS	18
Figure 10	Genomic organization of the three known members of the human *SOD* family	32
Figure 11	Possible cellular and humoral immune mechanisms in vitiligo	45
Figure 12	Different pathways for melanocyte destruction	49
Figure 13	Mechanism of action of TNFα	52
Figure 14	*HLA* region on chromosome 6q21	56
Figure 15	*TNFA* gene structure and known polymorphims	57
Chapter 2	**Role of superoxide dismutase 1 (SOD1) in vitiligo susceptibility**	
Figure 1	Lipid peroxidation (LPO) levels in controls and vitiligo patients	144
Figure 2	SOD1 activity in controls and vitiligo patients	145
Figure 3	Relative gene expression of *SOD1* in controls and vitiligo patients	147
Figure 4	Western blot analysis of erythrocyte SOD1 and GAPDH protein	148
Figure 5	Densitometric analysis of SOD1 and GAPDH protein levels in controls and vitiligo patients	149
Figure 6	PCR-RFLP analysis of *SOD1* C/T (Ile40Thr) polymorphism	150
Figure 7	HRM analysis of *SOD1* gene in vitiligo patients and controls	154
Figure 8	Representative *BLAST* analysis for *SOD1* sequence	155
Chapter 3	**Role of superoxide dismutase 2 (SOD2) in vitiligo susceptibility**	
Figure 1	PCR-RFLP analysis of *SOD2* C/T (Leu84Phe) and C/T (Thr58Ile) polymorphisms	174

Figure 2	TaqMan end point fluoroscence analysis for *SOD2* Val16Ala (T/C)	176
Figure 3	Relative gene expression of *SOD2* in controls and vitiligo patients	183
Figure 4	SOD2 specific activity in controls and vitiligo patients	185
Chapter 4	**Role of superoxide dismutase 3 (SOD3) in vitiligo susceptibility**	
Figure 1	PCR-RFLP analysis of *SOD3* C/G (Arg213Gly) and G/A (Ala40Thr) polymorphism	208
Figure 2	Relative gene expression of *SOD3* in controls and vitiligo patients	213
Figure 3	SOD3 activity in controls and vitiligo patients	215
Chapter 5	**Evaluation of oxidative stress and autoimmune hypotheses in onset and progression of vitiligo**	
Figure 1	Lipid peroxidation (LPO) and antimelanocyte antibody levels in controls and vitiligo patients	227
Figure 2	Lipid peroxidation (LPO) and antimelanocyte antibody levels with respect to onset and progression of disease	228
Chapter 6	**Role of tumor necrosis factor α (TNFα) in vitiligo susceptibility**	
Figure 1	PCR-RFLP analysis of *TNFA* promoter polymorphisms	241
Figure 2	Linkage disequilibrium (D') among *TNFA* promoter SNPs in generalized and localized vitiligo patients	246
Figure 3	Age of onset of the disease in vitiligo patients	250
Figure 4	Relative gene expression of *TNFA* in controls and vitiligo patients	252
Figure 5	Serum TNFα levels in controls and vitiligo patients	254
Figure 6	Relative gene expression of *ICAM1* in controls and vitiligo patients	256
Chapter 7	**Role of tumor necrosis factor-β (TNFβ) in vitiligo susceptibility**	
Figure 1	PCR-RFLP analysis of *TNFB* +252G/A polymorphism	276
Figure 2	TaqMan end point fluoroscence analysis for *TNFB* A/C; (Thr26Asn) using dual color hydrolysis probes	281
Figure 3	Age of onset of the disease in vitiligo patients	283
Figure 4	Relative gene expression of *TNFB* in controls and vitiligo patients	288
Figure 5	Melt curve analysis of *TNFB* and *GAPDH* showing specific amplification	289